Allogene Therapeutics, Inc. (ALLO) Stock

Allogene Therapeutics, Inc. (ALLO) is a Healthcare stock trading at $2.09 (as of 2026-08-20), with a market capitalization of $721.37M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer, including CAR T and related product candidates. Its pipeline includes UCART19 and multiple allogeneic CAR T programs targeting CD19 and other antigens, aimed at treating patients across settings such as B-cell ALL and non-Hodgkin lymphoma, with additional candidates in trials for multiple myeloma and other malignancies.

Understand Allogene Therapeutics, Inc.: how it makes money

Allogene Therapeutics develops, manufactures, and commercializes genetically engineered allogeneic T cell therapies for cancer, including UCART19, and it also advances additional anti-CD19 allogeneic CAR T candidates through clinical trials; it generates revenue via collaboration agreements.

The company’s reported revenue in the latest quarter is collaboration-based (including related party collaboration revenue), so changes in collaboration economics, rather than recurring product sales alone, are the structural profit model driver at this stage.

Revenue by segment (latest quarter)
Collab$0.0B
Collab Related$0.0B

Business quality (Weak): Latest-quarter revenue is 0.0B with a deeply negative operating margin, so interpret profit performance as development-stage and focus on trial execution and clinical program KPIs.

Bull case

  • Strong ALPHA3 operational execution: 98% of enrolled patients received allogeneic therapy within the median time, and 50 Semicel Phase 2 Alpha 3 trial sites were activated.
  • Clinical endpoint signals for the Semicel arm in ALPHA3: Measurable residual disease clearance rate for the Semicel arm was 58.3%, versus 16.7% for the observation arm, with an absolute difference of 41.6%.

Bear case

  • No collaboration revenue reported in the latest quarter: Collaboration Revenue and Collaboration Revenue - Related Party were both 0.0B for the quarter ended 2024-03-31.
  • Development-stage financial pressure: Operating margin was -315927.3 for the quarter ended 2024-03-31, consistent with heavy spending before sustained revenue generation.
  • Program stage risk remains elevated: The company’s ALLO-501 and ALLO-501A programs are in Phase I and Phase I/II clinical trials, which can imply longer timelines to definitive results.
Valuation — source: SEC EDGAR (first-party)
Price$2.09
Market Cap$721.37M
Price / Book1.65
Price / Sales155.47
FCF Yield-26.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)-34.1%
FCF Growth (YoY)-25.6%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.30 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderPfizer Inc ($49.79M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid D. Chang
Employees226
CountryUS
IPO Date2018-10-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Candel Therapeutics, Inc. (CADL)
  • 4D Molecular Therapeutics, Inc. (FDMT)
  • Aura Biosciences, Inc. (AURA)
  • Tectonic Therapeutic, Inc. (TECX)
  • Prime Medicine, Inc. (PRME)
  • Eikon Therapeutics, Inc. Common Stock (EIKN)
  • REGENXBIO Inc. (RGNX)
  • Artiva Biotherapeutics, Inc. (ARTV)
ALLO earnings history · ALLO institutional & insider holders · ALLO KPIs & operating metrics · ALLO financials · ALLO investor presentations & press releases · ALLO SEC filings · ALLO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.